Education
About Us
Working with TipRanks
Follow Us
Lyra Therapeutics (LYRA)
NASDAQ:LYRA
LYRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.81 - $37.50
Previous CloseN/A
Volume832.93K
Average Volume (3M)25.22K
Market Cap
$11.82M
Enterprise Value$14.78M
Total Cash (Recent Filing)$29.78M
Total Debt (Recent Filing)$32.48M
Price to Earnings (P/E)―
Beta2.45
Next Earnings
Nov 11, 2025EPS Estimate
-5.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.51
Shares Outstanding1,644,454
10 Day Avg. Volume15,816
30 Day Avg. Volume25,218
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue19.19
Enterprise Value/Gross Profit25.93
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$23.00Price Target Upside219.89% Upside
Rating ConsensusHold
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe recent positive pivotal Phase 3 ENLIGHTEN-2 trial challenges the previous negative results from Phase 3 ENLIGHTEN-1, offering new hope for the development of LYR-210.
Market PotentialIf the pursuit of LYR-210 FDA approval focuses on the CRSsNP patient population, it targets roughly 70% of CRS patients, which represents a significant portion of the market.
Bears Say
Stock Price ConcernsShares are seen as range-bound without a meaningful data catalyst, leading to a Neutral rating reiteration.
Strategic ChallengesThe greatest strategic hurdle for LYRA is reconciling the discrepancy between the positive ENLIGHTEN-2 trial and the negative ENLIGHTEN-1 trial.
Lyra Therapeutics News
LYRA FAQ
What was Lyra Therapeutics’s price range in the past 12 months?
Lyra Therapeutics lowest stock price was $3.81 and its highest was $37.50 in the past 12 months.
What is Lyra Therapeutics’s market cap?
Lyra Therapeutics’s market cap is $11.82M.
When is Lyra Therapeutics’s upcoming earnings report date?
Lyra Therapeutics’s upcoming earnings report date is Nov 11, 2025 which is in 75 days.
How were Lyra Therapeutics’s earnings last quarter?
Lyra Therapeutics released its earnings results on Aug 12, 2025. The company reported -$5.51 earnings per share for the quarter, beating the consensus estimate of -$5.527 by $0.017.
Is Lyra Therapeutics overvalued?
According to Wall Street analysts Lyra Therapeutics’s price is currently Undervalued.
Does Lyra Therapeutics pay dividends?
Lyra Therapeutics does not currently pay dividends.
What is Lyra Therapeutics’s EPS estimate?
Lyra Therapeutics’s EPS estimate is -5.26.
How many shares outstanding does Lyra Therapeutics have?
Lyra Therapeutics has 1,644,454 shares outstanding.
What happened to Lyra Therapeutics’s price movement after its last earnings report?
Lyra Therapeutics reported an EPS of -$5.51 in its last earnings report, beating expectations of -$5.527. Following the earnings report the stock price went up 8%.
Which hedge fund is a major shareholder of Lyra Therapeutics?
Currently, no hedge funds are holding shares in LYRA
Lyra Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$23.00 (219.89% Upside)
$23.00 (219.89% Upside)
Blogger Sentiment
Bullish
LYRA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 605.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.00%
12-Months-Change
Fundamentals
Return on Equity
-238.26%
Trailing 12-Months
Asset Growth
-44.42%
Trailing 12-Months
Company Description
Lyra Therapeutics
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
LYRA Stock 12 Month Forecast
Average Price Target
$23.00
▲(219.89% Upside)
Technical Analysis
Brainstorm Cell Therapeutics
―
GT Biopharma
―
Genprex
―
Spruce Biosciences
―
Conduit Pharmaceuticals
―
Ownership Overview
3.27% Insiders
3.85% Mutual Funds
24.14% Other Institutional Investors
61.86% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---